Myovant Sciences (MYOV) Reaches New 1-Year High at $19.10

Myovant Sciences Ltd (NYSE:MYOV)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $19.10 and last traded at $19.11, with a volume of 112898 shares. The stock had previously closed at $16.92.

A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of Myovant Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, February 20th. Cowen reiterated a “buy” rating on shares of Myovant Sciences in a report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Myovant Sciences presently has a consensus rating of “Buy” and a consensus price target of $22.50.

The stock has a market capitalization of $994.13, a price-to-earnings ratio of -9.74 and a beta of -0.04. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.04 and a quick ratio of 5.04.

Myovant Sciences (NYSE:MYOV) last issued its quarterly earnings results on Tuesday, February 13th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.28). equities analysts expect that Myovant Sciences Ltd will post -2.07 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in MYOV. Ardsley Advisory Partners acquired a new position in Myovant Sciences in the fourth quarter valued at $1,272,000. Point72 Asset Management L.P. acquired a new position in Myovant Sciences in the third quarter valued at $1,255,000. Goldman Sachs Group Inc. acquired a new position in Myovant Sciences in the second quarter valued at $174,000. Finally, JPMorgan Chase & Co. lifted its holdings in Myovant Sciences by 18.4% in the third quarter. JPMorgan Chase & Co. now owns 91,213 shares of the company’s stock valued at $1,382,000 after buying an additional 14,203 shares during the period. Institutional investors and hedge funds own 81.44% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with's FREE daily email newsletter.

Leave a Reply